Cargando…

Production of Sm-153 With Very High Specific Activity for Targeted Radionuclide Therapy

Mostrar otras versiones (1)

Samarium-153 ((153)Sm) is a highly interesting radionuclide within the field of targeted radionuclide therapy because of its favorable decay characteristics. (153)Sm has a half-life of 1.93 d and decays into a stable daughter nuclide ((153)Eu) whereupon β(−) particles [E = 705 keV (30%), 635 keV (50...

Descripción completa

Detalles Bibliográficos
Autores principales:	Van de Voorde, Michiel, Duchemin, Charlotte, Heinke, Reinhard, Lambert, Laura, Chevallay, Eric, Schneider, Thomas, Van Stenis, Miranda, Cocolios, Thomas Elias, Cardinaels, Thomas, Ponsard, Bernard, Ooms, Maarten, Stora, Thierry, Burgoyne, Andrew R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8326506/ https://www.ncbi.nlm.nih.gov/pubmed/34350194 http://dx.doi.org/10.3389/fmed.2021.675221

Ejemplares similares

Production of Sm-153 With Very High Specific Activity for Targeted Radionuclide Therapy
por: Van de Voorde, Michiel, et al.
Publicado: (2021)

Exploring the Potential of High-Molar-Activity Samarium-153 for Targeted Radionuclide Therapy with [$^{153}$Sm]Sm-DOTA-TATE
por: Vermeulen, Koen, et al.
Publicado: (2022)

Exploring the Potential of High-Molar-Activity Samarium-153 for Targeted Radionuclide Therapy with [(153)Sm]Sm-DOTA-TATE
por: Vermeulen, Koen, et al.
Publicado: (2022)

Separation of samarium and europium by solvent extraction with an undiluted quaternary ammonium ionic liquid: towards high-purity medical samarium-153
por: Van de Voorde, Michiel, et al.
Publicado: (2018)

Bismuth-213 for Targeted Radionuclide Therapy: From Atom to Bedside
por: Ahenkorah, Stephen, et al.
Publicado: (2021)

Dosimetric implications of the potential radionuclidic impurities in (153)Sm-DOTMP
por: Wendt, Richard E., et al.
Publicado: (2022)

Radiolabeling of Human Serum Albumin With Terbium-161 Using Mild Conditions and Evaluation of in vivo Stability
por: Cassells, Irwin, et al.
Publicado: (2021)

Resonant laser ionization and mass separation of $^{225}$Ac
por: Johnson, Jake D, et al.
Publicado: (2023)

Resonant laser ionization and mass separation of (225)Ac
por: Johnson, Jake D., et al.
Publicado: (2023)

CERN-MEDICIS: A Unique Facility for the Production of Non-Conventional Radionuclides for the Medical Research
por: Duchemin, Charlotte, et al.
Publicado: (2021)

Efficient Production of High Specific Activity Thulium-167 at Paul Scherrer Institute and CERN-MEDICIS
por: Heinke, Reinhard, et al.
Publicado: (2021)

Efficient Production of High Specific Activity Thulium-167 at Paul Scherrer Institute and CERN-MEDICIS
por: Heinke, Reinhard, et al.
Publicado: (2021)

Radionuclide Treatment with 153Sm-EDTMP is Effective for the Palliation of Bone Pain in the Context of Extensive Bone Marrow Metastases: A Case Report
por: Kairemo, Kalevi, et al.
Publicado: (2014)

Production of innovative radionuclides for medical applications at the CERN-MEDICIS facility
por: Bernerd, C, et al.
Publicado: (2023)

Novel radionuclides for use in Nuclear Medicine in Europe: where do we stand and where do we go?
por: Radzina, Maija, et al.
Publicado: (2023)

The influence of Sm-153 therapy on bone marrow function
por: Małkowski, Bogdan, et al.
Publicado: (2016)

Treatment efficacy of (153)Sm-EDTMP for painful bone metastasis
por: Ayati, Narjess, et al.
Publicado: (2013)

The CERN-MEDICIS Isotope Separator Beamline
por: Martinez Palenzuela, Yisel, et al.
Publicado: (2021)

The CERN-MEDICIS Isotope Separator Beamline
por: Martinez Palenzuela, Yisel, et al.
Publicado: (2021)

Optimisation of clinical SPECT imaging with 155Tb for theragnostic radionuclide therapy
por: Cocolios, Thomas Elias, et al.
Publicado: (2016)

Systemic Radiopharmaceutical Agents (Sm-153) may be Dangerous in Hepatacellular Carcinoma
por: Keskin, Onur, et al.
Publicado: (2015)

VeriSM(TM) unwrapped and applied
por: Agutter, Claire, et al.
Publicado: (2018)

Comparison of Tc-99m MDP and Sm-153 EDTMP bone scan
por: Ramachandran, Krishnakumar, et al.
Publicado: (2011)

Non-conventional radionuclides in personalised medicine
por: Stora, Thierry
Publicado: (2023)

Comparison of Image Quality of Different Radionuclides Technetium-99m, Samarium-153, and Iodine-123
por: Bouzekraoui, Youssef, et al.
Publicado: (2019)

[(153)Sm]Samarium-labeled FAPI-46 radioligand therapy in a patient with lung metastases of a sarcoma
por: Kratochwil, Clemens, et al.
Publicado: (2021)

Evaluation of Therapeutic Efficacy and Imaging Capabilities of (153)Sm(2)O(3)-Loaded Polystyrene Microspheres for Intra-Tumoural Radionuclide Therapy of Liver Cancer Using Sprague-Dawley Rat Model
por: Tan, Hun Yee, et al.
Publicado: (2023)

Toxicity of Therapy with Sm-153-EDTMP: To What Extend can it be Related to the Tumor Type?
por: Świętaszczyk, Cyprian, et al.
Publicado: (2016)

Bone Metastases Treatment by Sm-153 Oxabifore in Combination with Monoclonal Antibody Denosumab (Xgeva)
por: Joob, Beuy, et al.
Publicado: (2014)

Combined use of zoledronic acid and 153Sm-EDTMP in hormone-refractory prostate cancer patients with bone metastases
por: Lam, Marnix G. E. H., et al.
Publicado: (2007)

Development of (153)Sm-DTPA-SPION as a theranostic dual contrast agents in SPECT/MRI
por: Gholami, Amir, et al.
Publicado: (2016)

VeriSM(TM) professional courseware
por: Morris, Helen, et al.
Publicado: (2019)

Preparation and Quality Control of the [(153)Sm]-Samarium Maltolate Complex as a Lanthanide Mobilization Product in Rats
por: Naseri, Zohreh, et al.
Publicado: (2011)

RADIOACTIVE CEMENT OF PMMA AND HAP-Sm-153, Ho-166, OR RE-188 FOR BONE METASTASIS TREATMENT
por: Montaño, Carlos Julio, et al.
Publicado: (2019)

A simple and automated method for (161)Tb purification and ICP-MS analysis of (161)Tb
por: McNeil, Scott W., et al.
Publicado: (2022)

Effectiveness of Bone Metastases Treatment by Sm-153 Oxabifore in Combination with Monoclonal Antibody Denosumab (Xgeva): First Experience
por: Rasulova, Nigora, et al.
Publicado: (2013)

Treatment of severe hypocalcaemia due to osteoblastic metastases in a patient with post-thyroidectomy hypoparathyroidism with (153)Sm-EDTMP
por: Kassi, Eva, et al.
Publicado: (2017)

Performance of paint coatings in the radiation fields of nuclear reactors and of high energy particle accelerators and after contamination by radionuclides
por: Schönbacher, Helmut, et al.
Publicado: (1977)

Radiation Safety Considerations in the Treatment of Canine Skeletal Conditions Using (153)Sm, (90)Y, and (117m)Sn
por: Wendt, Richard E., et al.
Publicado: (2020)

Terbium Radionuclides for Theranostics Applications: A Focus On MEDICIS-PROMED
por: Formento Cavaiera, R, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_roafvmqtfguui214v59tenrk2k